Explore the power of
high-plex protein
profiling to your
cardiovascular disease
research
Discovery, validation, and development in a single proteomics platform
Gain deeper insights with proteomics
See you soon at AHA annual meeting In Philadelphia!
Join our scientific sessions (details below), and then stop by booth 2917 to experience the power of the SomaScan® Assay. We look forward to hearing about your cardiovascular disease (CVD) research needs and discussing how we can help advance your novel biomarker discoveries with our high-plex protein profiling platform.
Attend our
CVD talk
Michael Hinterberg, PhD, Senior Scientist from SomaLogic, shares findings on “Applying Proteomic CV and Kidney Prognosis Risk in T2D Patients to Identify High-Risk Patients.”
See our
5 CVD posters
Explore the latest research in cardiovascular disease using high-plex proteomics.
Stop by
booth 2917
Come by our booth to speak to our team and share more about your CVD research.
PRESENTATION
Applying Proteomic CV and Kidney Prognosis Risk in Type 2 Diabetes (T2D) Patients to Identify High-Risk Patients
Sunday, Nov 12, 2023 | 8:30-8:45AM | Location: 204A
Presenter: Michael A. Hinterberg, PhD
Senior Scientist at SomaLogic
Join us Sunday to explore the interdependence of cardiovascular and kidney health in T2D. Proteomic surrogate models for cardiovascular risk and kidney prognosis have been developed and validated, but not in a combined manner in T2D patients.
Learn more at our poster sessions
| Session Title | Presenter | Date and Time |
|---|---|---|
| Using the proteome to detect biomarkers of cardiovascular comorbidities | Yolanda Hagar, PhD |
Saturday, Nov 11, 2023 3:00-4:15 PM |
| Statin signature: Using proteomics to detect pharmacological fingerprints | Clare Paterson, PhD |
Monday, Nov 13, 2023 10:30-11:45 AM |
| Utilization of proteomic surrogates for early detection of unexpected drug benefits | Steve Williams, MD, PhD |
Monday, Nov 13, 2023 10:30-11:45 AM |
| Using a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease | Clare Paterson, PhD |
Monday, Nov 13, 2023 1:30-2:45 PM |
| Comparison of Proteomic CV Risk to Established ASCVD 10-year Risk Decision Points | Michael A. Hinterberg, PhD | Monday, Nov 13, 2023 1:30-2:45 PM |
*Each poster presentation will be held in the Science & Technology Hall, Level 2, Hall A-D